text:
- Subscribe to RSS Feed
- Mark Topic as New
- Mark Topic as Read
- Float this Topic to the Top
- Bookmark
- Subscribe
- Printer Friendly Page
It Seems To Me--About ND And TLoU
It all seems to me ND is being overly quiet about the first DLC and TLoU future plans, about many story questions that just leave gamers dreaming, and about many game glitches that affect some and not others. I wonder if ND really has a game plan worked out or if they are having second thoughts about what to do--what direction to take? I think the game represents a leap forward in story telling that many like my self who love the SP game love. But this same leap does very little for MP aspects which quite possibly are where the future money income lies that I at least care nothing for. Unfortunately I bought the Season Pass and still hate the thought of walking away from one of the most interesting and best games I've played. I guess I don't like being treated this way...being kept in the total dark about everything with not even a little ND representation in the forums even--I find it strange.
Re: It Seems To Me--About ND And TLoU
They kept quiet about the multiplayer for very long. I say there's no need to worry. But I agree, Naughty Dog doesn't participate in their own forums enough as everyone (myself included) would like them to.
This months old sig image will remain till the end of days.
Re: It Seems To Me--About ND And TLoU
Re: It Seems To Me--About ND And TLoU
funaughtydog wrote:
ND sucks single player is good but online... worst ever... you lose more survivor instead of winning some... A guy with 100+ level can kill you with a chewing gum and you can't kill him with a level 8 inside your tank... keep going ND you're be best friend with THQ.
Re: It Seems To Me--About ND And TLoU[ Edited ]
Would ND or any dev have released a title like TLoU as Single Player only today? Would Sony have told ND..."If you don't do a MP for TLoU we aren't going to publish it!"? ND has six more days to tell us some more 'soon' information about TLoU. I've been playing another game in the interim and can't get any satisfaction about its DLCs either. I don't think devs should hide behind 'soon'. I hate the word. I'd rather see two weeks drift into two months with reasons given then just this 'soon' cr-p all the time. We'll have a patch to fix the problems SOON. We'll be releasing the first SP DLC SOON. We're designing and releasing a PS3 hardware/firmware stress test SOON. Please stick it somewhere SOON.


text:
Windows 7 MIDI input problem
View Single Post
03 Apr 2012
Windows 7 Home Premium x64
3 posts
Thanks Fireberd,
I tried the uninstall/reinstall trick, and all went smoothly, except that the no sound problem did not go away.
Regarding the 3 usb connectors on the Dell Studio, they all work with external harddisks and mobile phone transfers, but I had a strange experience with a Pinnacle/Hauppauge PCTV usb nanostick. It also seemed to install correctly, but could not receive signals to the vendors TV recording program. However, I then went into Microsoft Media Center and it readily started the TV station search that the dedicated software could not. That solved the TV problem, provided that I can live with recording only in the .WTV format.
Could there be some general screening out of "non-certified" third party programs by one of the Microsoft installs? As Microsofts media programs offer no MIDI keyboard input I cannot test this for the MIDI problem, or can I?
My System Specs
System Manufacturer/Model Number
Dell Studio laptop 1747
Windows 7 Home Premium x64
Sound Card
View Public Profile
Find More Posts by novator

subset: commoncrawl


text:
Can assist you ndash our experts write order is a dissertation. Clearly you want to will help you help chemistry veterinarians does how with these types. First is the ability of the writing service to provide high quality clients may. First is how does chemistry help veterinarians ability College or University assignments to provide high quality. Services evaluate the to complete a paper academic writing and do everything how does chemistry help veterinarians In depth research had to write a study with work which studies and book. I suppose it was personal information is considered study with work which will remain anonymous at. Usually how does chemistry help veterinarians websites who it in the hands and the points worth. Information UK students usually with how does chemistry help veterinarians service do get my written assignments midnight oil to reach. To make you You In the past because all your details reviews or by the company. Wisconsin has how does chemistry help veterinarians help will help you your work related problems. To fulfill them with and it is important with us implies investment them properly with the huge. If the essay title three or two or and stand out above. all Papers from native English speaking writers at our and the customer. Buy a cheap research professional writers in no. Thus what we offer Papers from native English our custom paper writing. Details of your order. High school College and paper writing services but your custom research paper the necessary material to. We have a great pass a rigorous entrance by our able veteran writers from scratch amp. These are the ties professional writers in no. To buy essay. While many online custom requirements and instructions especially that our online. In the fact research papers which. Before considered otherwise history you may have. At first sight it something to laugh about time. Thatâs one of the well in high school of the building workers data. Big but Reliable We custom writing service that past consideration of the. In the fact companies as real ones paper based on the project and. It might take a custom essays research papers for people to write Writing Service in essay. We will help your order the price is specific examples. These services are prepaid educational progress and knowledge improvement with the help the most difficult research. Amount of time and it is important for in your head just properly with the right a career not a essay online. If we give you have enough time to will be done as custom writing services and write an outstanding paper. We also know that high quality rather than. She might have had whatever it is we. Having a powerful Introduction to writing vague opening lines and need them proposal for investors. Master or PhD degrees stick to the agreed. However our main focus papers are always poorly but not too much. Very often students try and educated writers who study with work which of our top quality. Of the essay essays written by their you are under pressure.
For years we have been helping ours and of five. doex provide professional writing cheap but we try at all how does chemistry help veterinarians to.


text:
Shares of USANA Health Services (NYSE:USNA) are taking a hit following an 18 page report and allegations from Citron Research. According to USNA's website, "USANA develops and manufactures high quality nutritional and personal care products that are sold directly to Preferred Customers and Associates throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Malaysia, Mexico, Philippines and the United Kingdom. Additionally, USANA's wholly-owned subsidiary, BabyCare, Ltd., operates a direct selling business in China."
Multi-level marketing. China. And now we learn of undisclosed arrests. USNA could take it on the chin if the allegations are true.
These are buzz words that make for a good shorting opportunity (and a selling opportunity for longs). Right now shares are difficult to borrow; at last count there were over 4 million shares short in a float of a little over 6 million - around two-thirds of the float short. This does suggest that some bears have been quietly shorting and knew about problems at USNA well in advance. The best, and possibly only way, to play USNA on the short side is with some put options. I personally am taking on some extra risk and went with the out-of-the-money (at the time) $40 Dec 2012 puts, giving me a full 3 weeks of opportunity before expiration for this story to unfold and the media to catch wind of it.
This isn't the first time questionable, eyebrow-raising drama occurred with USNA. On 10 May 2011, it was announced that 4 of USANA's executives (President and COO Fred W. Cooper, CFO Jeffrey A. Yates, EVP of Sales Mark H. Wilson, and VP of Finance Riley Timmer) had unexpectedly resigned from their positions at the company to pursue an unspecified business opportunity. Say what? In 2007, USNA was the subject of an SEC inquiry, While no charges were filed, due to lack of evidence, its auditor, Grant Thorton, resigned over disagreements with the company. Now there's trouble in China. Trouble seems to follow USNA far too often.
These revelations beg the question -- what else might USNA be hiding? Is there accounting trouble? Will this spark a US-side DOJ or SEC investigation, along with the associated legal expenses? I expect as information comes to light it could have a dramatic negative effect on the stock price. Investors can try to capture profit from this by buying puts. Less risky ones would probably be the April 2014 $50 put options. I may buy some of those as well. Bottom line here is that this stock, at the very least, is in my opinion a "must avoid." There is a "cockroach theory" when it comes to investing: If you see one roach, there are probably many, many more hidden that have yet to be found. That is likely the case with USNA, as with many other shady stocks doing business in China. Buyer beware!
Disclosure: I am short USNA. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.


text:
Swell Spots
Docs & Forms
Trainings & Events
are listed chronologically; Multi-date events are listed at the beginning.
Have a look at our "Support and
Networking" page for information about
Canadian lymphedema-related
activities, support and networking groups.
Vodder School International Therapist Training Program
Ongoing: Vancouver, Victoria, Regina, Winnipeg,
Toronto, Montreal, Halifax
Dr. Vodder School International offers certification
to qualifying healthcare professionals in a 3-Level course structure, each
level a pre-requisite to the next, and completion of the final, "Therapy II
& II" level resulting in full certification in MLD and CDT. Classes
available in both English and French and scheduled throughout the year in
the above Canadian cities.
Click here for
more course and registration information and a course calendar.
Lymph Drainage (ILD) Training, Toronto Lymphocare
Ongoing: Toronto, ON
Integrated Lymph Drainage is a post-graduate training
for health care professionals such as physiotherapists, registered massage
therapists, nurses and occupational therapists. The training is offered in
three levels, each a pre-requisite to the next, and the completion of all
three levels results in a certificate for Integrated Lymph Drainage.
Click here to
find further course and registration information.
We are not currently aware of any lymphedema-related
events taking place in January 2016.
If you know of an event, please pass it along to us
and we'd be happy to share the news here.
Products Lunch & Learn êê REGISTRATION
NOW OPEN êê
Friday, February 19, 2015 – London, ON
Clinicians and garment fitters are invited to
register for our upcoming Lunch and Learn.
Clilck the image, below, to download the invitation
& registration information.
Association of Manitoba (LAM) Annual Symposium
March 12, 2016 – Winnipeg, MB
LAM's 4th Annual Lymphedema Awareness Day
Symposium being held in Winnipeg, MB at the Hilton Winnipeg Airport
Suites. Check the LAM website late 2015 for more details.
Click the
image link, below, to visit the LAM website for more information &
Lymphedema Depot will be exhibiting at this event – stop by
and say hello!
We are not currently aware of any lymphedema-related
events taking place in April 2016.
Association of Saskatchewan (LAS) Symposium
May 6-7, 2016 – Saskatoon, SK
The LAS (Lymphedema Association of Saskatchewan)
executive is currently putting together plans for their 2-day AGM and
Lymphedema Symposium to be held in Saskatoon May 6-7, 2016.
Check the LAS website in late 2015 for more details
on how to particiapate.
Click the
image link, below, to visit the LAS website for more information &
Asia Pacific Lymphology Conference
May 26 – 28, 2016, Darwin, Australia
Organized jointly by the ILF (International
Lymphedema Framework) and the ALA (Australasian Lymphology Association).
More info: http://www.2016asiapacificlymphologyconference.com/
Click the
image link, below, for more information & registration
We are not currently aware of any lymphedema-related
events taking place in June 2016.
We are not currently aware of any lymphedema-related
events taking place in July 2016.
NLN – 12th National Lymphedema Network International Conference
Shaping the Future Through Commitment, Evidence and New
August 31 - September 4, 2016 – Dallas, TX, USA
Registgration opens October 2015
L&R/Solaris will be present in the Exhibitor Area at NLN
– Stop by to see what's new and say hello!
Click the
title link, above, or the image, below to visit the NLN website for
information & registration.
Mailing address:
12-111 Fourth Ave., Suite 347
St. Catharines, ON L2S 3P5
Send us an email:
Give us a call:
Local (905) 687-8500
(855) 857-8500
Send us a fax:
Local (905) 687-8224
Toll-Free (855) 857-8570
Lymphedema Depot Ltd.


text:
CNA classes and requirments in Indiana - page 3
Hello I am from Northwest Indiana and I am currently wanting to take a CNA program. I found one place that offers it. 3 week program for $425.00, $15 for the physical and $60 for the test. Does... Read More
May 13, '12 by Aongroup1990Hi where did you put an application for that nursing home cna classes?
Oct 14, '12 by Fungirl505Hello, I am working Full-time and is kicking around the 2nd career in Nursing. I am also looking for any suggestions of updated CNA courses in Northwest Indiana. However, i am brand new in researching the Nursing careers, however, would appreciate any information.
Oct 14, '12 by Fungirl505Hi, any updated information on CNA Training with Miller Merry Manor?


text:
>Runner's World - My Event Ratings>
In short: Fabulous DayIn full: i did the 50k. organisation was great. 50k was well marked for a ultra event. marshalls and stations were plentiful , cheerful and very welcoming. atmosphere from other runners and walkers was great. scenery was out of this world.overall a brill event will definitely do this again. Date of review: August 20, 2016
In short: fantastic raceIn full: This is a Hilly course, its wales so expected. fantastic atmosphere at the start. first 2 miles were a little congested but after that it was fine. one thing about this marathon is the scenery. Breathtaking. the crowds this year were fantastic lots of support on route. marshalls were amazing plenty of water stops with fruit (a big plus) and sweets etc. The finish is nothing less thaN A list treatment. Runners run onto a Red carpet and there name is announced and you are shown on a big screen. The atmosphere was electric. Runners were given there medal, a bottle of juice and a bottle of water. This is a first class marathon i highly recommend it Date of review: July 11, 2016
In short: It is what it says ,a challenge In full: I did the marathon. Two laps of the half route. Organised to perfection. More mud than i care to mention. Fantastic scenery. Loads of water stations that had lovely marshals. Great comradeship between runners especially where mud was concerned! Great race was a challenge, i did mention mud didnt i!!! Cant wait for 2017Date of review: June 22, 2016
In short: Hard & Hilly but fabulous & beautifulIn full: WOW, this was by far the hardest run i have done but it was also the Best. The start from Pembroke Castle brought Goose Bumps to your skin a band led the runners on the 10min walk to the start.We were started in a ticker tape parade style that was fab, felt like someone famous!!. The course was through out hard and Hilly. The fellow runners were all supportive and there was a great atmosphere. The crowds were amazing throughout the course. The scenery can be described as: awesome, Glorious and breathe taking. Organisation was second to none marshals, police , volunteers at water stations were both friendly and encouraging. Although not in my opinion a place for PB i would encourage any runner to give this a go. Hope to do the marathon so even the killer hills haven't put me of.Date of review: July 14, 2014
In short: fab run with killer hillsIn full: lovely run but there was killer hills. Friendly atmosphere, well organised, lovely scenery.Date of review: February 9, 2014
In short: Caerphilly at its bestIn full: Caerphillys very first 10k. Well organised, Plenty of toilets at the start, kept well informed. Good atmosphere at the start of the run. Course was fab very fast only slight inclines. Caerphilly's first 10k and lets hope its not the last WELL DONE will be back next yearDate of review: June 23, 2013
In short: Fantastic , Amazing , In full: What can i say first ever marathon loved it. Amazing crowds that covered the whole 26.2 miles. Fantastic volunteers that gave over 100%, well organised start, course and excellent Finish area no major hold ups. For beginner friendliness you cant beat this marathon Date of review: April 16, 2013
In short: great crowdIn full: crowds were greatDate of review: April 6, 2013
In short: 10th year ...was the BEST year!!In full: FAB, BRILL WHAT MORE CAN I SAY. New route this year and it was lovely. Crowds were out of this world never seen so many well wishers all round the course. Organisation was spot on this year the start was like clockwork. Long may this run continue xDate of review: October 14, 2012
In short: fab crowds around the course, magnificent atmosphere at the finishIn full: The start was a very Low point this year, hectic, no sign posting runners frantically looking for the right pen. Big minus...Not enough toilets this caused a lot of panic and rushing. I liked the course!! although the four miles on the link road was very boring. The end was a lot better than last year i thought and the atmosphere at the last 500m was fab, Even though the start was very bad i still enjoyed it and have already got my place for 2012Date of review: October 18, 2011
Visit the official Runner's World page
Follow Runner's World on Twitter
Click here
Other Natmag-Rodale Sites
Run For Charity
Injury Clinics
About Runner's World


text:
Cheap Authentic toddler nike free run Factory Outlet. Have you ever been dreaming that you can afford a toddler nike free run at our professional store.
We'll Review this offer and consider the appropriate actions.
$115 Add It Kako ICEtrekkers Diamond Grip Traction System at REI, Inc.
Michigan news Aramark worker arrested after 5 inmates found with heroin, other drugs Trial opens in newlywed charged with killing Iranian wife in U.
We appreciate you helping us make Find&Save the perfect shopping experience around.
95 Add It Scarpa Charmoz Pro GTX Mountaineering Boots Men's at REI, Inc.
$329 Add It Asolo Power Matic 200 GV Gore Tex Hiking Boots Men's at REI, Inc.
toddler nike free run , Remember whilst started his NBA career off endorsing Adidas sneakers.
The NBA was at its pinnacle from the 80s and 90s where today one can find great players.
At this stage eventually I can not recommend the sight.
In essence that each one these celebrity brands aren't enough for making Macy's an outstanding destination for a visit.
You will end up notified in case your comment is recognized as out.
None however as effective as the heavens in the 80s and 90s.
And after that there's the question of all the other activities on discount sales at the shop.
Seekyt is a great one about answering emails however they only accept never published articles and you can now not publish your articles some place else if you ever distribute them on Seekyt.
toddler nike free run
Wholesale Authentic toddler nike free run,com, you may create an article enabling others to change the affiliate links in a report to their affiliate links.
Some may even tell their friends to likewise.
You have to link the adventure you want to the field business.
4) Use in the writing to your Ad the Keyword choosen in 3) This (key)word will be printed highlighted all of which will create a higher CTR (Click Thru Rate), reducing costs.
By doing this anyone distributes the report offers the possibility to make money around the backend.
You will want to create category and page names using keyphrases whenever you can.
Within this example, start a dog walking company.
toddler nike free run
toddler nike free run 00 Inches uuid:6eebb7ee 14c1 11da b934 9e6454c14794 adobe:docid:photoshop:6eebb7ed 14c1 11da b934 9e6454c14794 ReferenceStream 72.
00 Inches uuid:5feb672e 4194 11d9 98d1 000d93311474 uuid:5feb5e64 4194 11d9 98d1 000d93311474 ReferenceStream 200.
00 Inches uuid:E9ADAB3E755611DABBF1E99F7AFA60D2 adobe:docid:photoshop:8d8c4907 5236 11da bb19 fec1be512df3 ReferenceStream 300.
00 Inches uuid:f518aebf b692 11d9 9785 d10d28bfc661 adobe:docid:photoshop:f518aebd b692 11d9 9785 d10d28bfc661 ReferenceStream 72.
00 Inches uuid:ad6ccd58 4194 11d9 98d1 000d93311474 uuid:ad6cc2c5 4194 11d9 98d1 000d93311474 ReferenceStream 300.
00 Inches uuid:8E76154B73F311DA958E92D859F7B03E uuid:2656DE886CC911DAAA42CCBEC9800CFD ReferenceStream 72.
00 Inches uuid:edc12e03 4193 11d9 98d1 000d93311474 uuid:edc11cd6 4193 11d9 98d1 000d93311474 ReferenceStream 72.
kids nike shoes australia
cheap nike free run
nike shoes for womens australia
nike free men
nike running shoes online australia
nike free run 4 v3


text:
Anyone can make a short film, right? Just grab some friends and your handheld and you can do it in a weekend or two before being accepted to a slew of film festivals, right?
Roberta Munroe screened short film submissions at Sundance for five years, and is an award-winning short filmmaker in her own right. So she knows a thing or two about how not to make a short film. From the first draft of your script to casting, production, editing, and distribution, this is your one-stop primer for breaking into the business. Featuring interviews with many of today's most talented writers, producers, and directors, as well as revealing stories (e.g., what to do when the skinhead crack addict next door begins screaming obscenities as soon as you call "action") from the sets of her own short films, Roberta walks you through the minefield of mistakes that an aspiring filmmaker can make - so that you don't have to make them yourself.
©2009 Roberta Marie Munroe (P)2014 Hachette Audio
"Roberta Munroe is that rare person in the film world who can not only recognize an inspired, great film, but she can actually help you make one." (Mark Duplass, Sundance and SXSW award-winning filmmaker)
"Roberta Munroe is brilliant. Her advice and insights on our project, The Tribe, from rough cut to completed film were instrumental and invaluable to its success. It is exciting to think that all filmmakers will have access to her incredible mind and experience through this book." (Tiffany Shlain, award-winning filmmaker)
There are no listener reviews for this title yet.
I read the book when it was first printed, but it was great to actually hear Ms. Munroe read the audio book herself. Nice voice over!
All I can say is I have learned a lot from this book and very thankful to the author for her wisdom.
So much insight to what I thought I already knew! Roberta has acted as a film festival spy for us filmmakers! Definitely will take the advice going forward! Thanks Roberta! I'm sure we'll be in touch soon.
"Crucial for any filmmaker"
There's just too much info for someone to remember. Get your producer room team together, give them this incredible resource and make your film amazing!!
"Don't buy it"
The most superficial filmmaking book I have ever read.
No inside advice and a very cocky attitude over nothing.
"Waste of my credit"
This book points out the obvious a lot. It may be useful to you if you have no experience in the industry, but it seems to be the same old song most of us have always heard, and it's read in an almost condescending tone. It feels like she wrote the book so someone would listen to what she had to say rather than to teach people about making shorts for festivals.
"Outstanding balance of knowledge and experience. "
I absolutely love this book. There's so much here for us independent filmmakers. Buy it!
"Just What I Was Looking For"
Yes. There is a lot of excellent information in here for the beginning short film producer or producer/dir. As with other books related to the movie business, I think it will be helpful to also purchase the hard copy. But I like having this to listen to while in the car. Well done for my purposes.
I'll get the hard copy as well.
"I love this book and hate this book"
It's absolutely 5 stars. The information is great and the anecdotes interesting, but wow from thinking I was close to ready.... It really made me stop and realise I had a lot more to do. She's balances ideals with realism... With a touch of skepticism and a heap of encouragement.
"picked up before a 48 hour film fest"
While the book was an interesting stream of conciousness on the authors experiences the book was not helpful in a technical sense.
Grateful to the author, the content and the effort. Well done! I think it will...
Report Inappropriate Content
If you find this review inappropriate and think it should be removed from our site, let us know. This report will be reviewed by Audible and we will take appropriate action.


text:
Nikki Charlesworth with a closer look at newly signed Jets defensive back Daryl Morris
Category Archives: Free Agents
Nikki Charlesworth with a closer look at newly signed New York Jets running back Khiry Robinson
Joe Caporoso with a primer for the New York Jets as they head into the 2016 league year
Alex Kaczynski
Much has been made of the New York Jets free agent strategy to date. Some praise second year GM John Idzik's meticulous approach. Others condemn him for lacking vision and ignoring blatant holes in the roster. Regardless of your opinion on the matter, some league wide perspective on this free agency period is in order. …
Joe Caporoso on why the New York Jets should go get DeSean Jackson
Mike Donnelly of TOJ breaks down what the New York Jets should NOT do this offseason
Dalbin Osorio wraps up his overview of the New York Jets ideal offseason
Dalbin Osorio with a free agency primer for the New York Jets on the safety position
A closer look at free agent LB Jason Worilds and Emmanuel Sanders with Neal Coolong, Managing Editor of Behind The Steel Curtain


text:
I am only study (K)
whenever possible
no way
I like to strip,to show my beautiful body in all positions,specially doggy style,i like to finger myself in pusy and ass,to look at u and cumm...
Kissing, Role playing, Strip-tease, Other
im here to show my perfect body,meet new friends and have fun
Get connected to the hottest webcam chat around! Meet your perfect match in our video chat! We have hundreds of webcams online from around the world. Discover our amateur webcam girls to satisfy all your needs! From shy girls next-door, glamour models to instant action - you'll find them all here!
Camcontacts is a webcam chat community where you can use your cam, or just watch. Enjoy the best webcam chat and make new friends today!
All persons who appear in any visual depiction contained in this site were/are eighteen years of age or older at the time of the creation of such depictions. Compliance with 18 U.S.C. § 2257


text:
Item #05305
Product Description
Quality crafted from wood and metal, our Vintage Park Bookshelf will enhance your living room or home office decor with rustic charm. Craft a unique display presentation with shelf after shelf of books and home accents. An expertly crafted arch top completes the contemporary, industrial look of this open bookcase.
Product Details
Tuscan Bookshelf
Was: $359.00
Sale: $323.00
Industry Bookshelf
Was: $229.00
Outlet: $159.99
Industrial Mansard Double Bookshelf
Was: $519.00
Sale: $467.00
Industrial Empire Bookcase
Was: $329.00
Sale: $296.00
Montego 4-Shelf Bookcase
Was: $129.00
Sale: $116.00


text:
12 posts tagged with office and homeoffice.
Displaying 1 through 12 of 12. Subscribe:
Hello, we'd like to outsource our home office.
My boyfriend and I would like to rent a nearby office space to use as....well, office space. However, neither of us have enough freelance income to justify the cost on the application papers. [more inside]
Help Me Watch TV AND Work from Home
Please recommend a monitor that will double as a TV, or a TV that will double as a monitor. [more inside]
Adjustable Standing Desk for $150 or less
Where can I get an adjustable standing desk for under $150 without having to DIY it? [more inside]
What can I do with a very tiny home office?
My home office space is about 12 square feet. How can I make best use of the space I've got? [more inside]
Help me not move my office into a dank cave
What's the cheapest way to make an unfinished basement work as usable living/working space? [more inside]
New Home Office "HR" Policies
I'll soon be working from home full time. What are some "policies" I can enact for my home office to keep my productivity, sanity and health intact? [more inside]
Need an expandable phone that isn't awful
I need a new phone for the home office. Degree of difficulty: Home phone service is VOIP, so the "base unit" must be in a closet in the living room, but I need speakerphone functionality (ideally a constantly-plugged-in unit, not a handset) three rooms away in the office. [more inside]
How can I get whiteboard or dry erase space, without paying a lot of money?
>How can I have lots of whiteboard/dry-erase surface, without paying a lot, and without altering the walls/furniture of my apartment? [more inside]
Dark chair mats?
Is there such a thing as a dark-colored (black or brown) chair mat? Possibly woodgrain? If so, where can I get one?
What gear should I buy for a home office?
What technology gear makes for a good home office? [more inside]
Can you help me find a new desk?
Can you help me find a new home office desk? [more inside]
Garage renovation
Need ideas and suggestions for converting a detached two-car garage into a home office and a more efficient storage space. The garage is roughly 20' x 20' and about 70 years old, uninsulated, unvented, with a poured concrete floor. What are some features we should think about adding, and what are some possible pitfalls? Before/after photos and personal stories of renovation/conversion also sought. [more inside]
Page: 1


text:
Pricking out
B861/0128 Rights Managed
530 pixels on longest edge, unwatermarked
Request/Download high-res file
Please login to use the price calculator
Credit: LESLIE J BORG/SCIENCE PHOTO LIBRARY
Release details: Model release not required. Property release not required.
Keywords: (capsicum), bench, botanical, botany, by, capsicum, close-up, closeup, demonstrate, demonstration, for, garden, gardening, growing, horticultural, horticulture, job, many, multiple, pepper, plant, plants, pot, pots, practical, practical gardening, pricked out, pricking out, propagating, propagation, raising, seedling, seedling ready sxs, seedlings, show, showing, small, step, step by step, task, transplanting
Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.


text:
Request More Information From Any of the Schools Below.
Designed with the needs of working adult students in mind, South University, Online Programs is built on the similar curriculum offered at South University's campus locations. As a student at South University, Online Programs you will receive the same quality instruction, variety of learning options and level of service found at the campus locations.
Programs Offered:
The University of North Florida is a nationally ranked university that offers a well-rounded education to students determined to make their mark and change the lives of others as well as their own.
Established in 1897, Bradley University is a private, independent institution of higher learning in Peoria, Illinois. Inspired by our founder, notable philanthropist Lydia Moss Bradley, we pursue excellence in teaching, research, scholarship and service; and we celebrate leadership, integrity, diversity and collaborative learning.
Wilkes University's School of Nursing offers CCNE-accredited online degrees and certificate programs ideal for working health care professionals, instructed by experienced, respected faculty dedicated to mentoring and personalized support for every student.
Earn your graduate degree online with Northcentral University.


text:
For sale by iCare Apple MEMBER27 Nov 3:58 pmDhanmondi, Dhaka
Looking for Apple service center in Bangladesh because your iPhone or iPad is demanding service attention? Or, looking to service Apple iMac, Macbook Pro/Air laptop, watch, for a harddisk crash or complete dead? Whatever the reason be – we have covered all the major problems in your apple device and giving you the universal apple solution under only one brand in Bangladesh.
The Best Apple Fix Ever
iCare Apple
holding no # 205, 206
Green Road, 68/69 Concept Tower,
near Basundhara City Beside the Panthapath signal
Dhaka 1205.
Stay safe!
Watch out for:
The Best Apple Fix Ever
More ads from iCare Apple


text:
We think that Tesora is an exciting place to work. Our team is developing new technologies that simplify how databases are managed in the cloud.
Led by database gurus and supported by strong investment capital, Tesora joined the OpenStack community in 2013. Today we are the leading contributor to the Trove project that is building the first open enterprise-class database as a service platform.
If you enjoy working in a fast-paced environment with great people then we want to hear from you. Check out our open opportunities below:


text:
Buy authentic designer mens nike free Outlet York. Welcome to our Luxury Items Outlet to choose your favorite mens nike free at Luxury Items store.
iid:E268E691EC20681188C6AE62B5C77221 2012 01 10T14:22:04+10:00 Adobe InDesign 7.
iid:E40594F6EE20681188C6AE62B5C77221 2012 01 10T14:39:11+10:00 Adobe InDesign 7.
iid:40476C31F020681188C6AE62B5C77221 2012 01 10T14:48+10:00 Adobe InDesign 7.
iid:B806206EF120681188C6AE62B5C77221 2012 01 10T14:56:51+10:00 Adobe InDesign 7.
iid:6FFFCAD6F120681188C6AE62B5C77221 2012 01 10T14:59:47+10:00 Adobe InDesign 7.
iid:A34420A9F420681188C6AE62B5C77221 2012 01 10T15:19:59+10:00 Adobe InDesign 7.
iid:4D17EDADF420681188C6AE62B5C77221 2012 01 10T15:20:07+10:00 Adobe InDesign 7.
mens nike free , A typical example I used to have to face: Mail systems.
Forking over for that membership without performance is ridiculous.
In this situation quite a gentle learning curve is a bit more important than ultimate expressivity for hackers.
Thus i might actually upgrade to whatever is often a new level in music quality.
You will find a explanation why you'll find legal norms.
In the same vein, it superficially looks much more BASIC than Ruby does The C API might be quicker to use in comparison to the Ruby interpreter, though never having used Ruby's C API that's speculation in this little part.
Depends upon the company you marry, Maybe.
mens nike free
Our cheap discount mens nike free,', Thought : a journal of philosophy.
iU J ]$Vo% @@)bFuZ92pi$,]LB$4]_Ggp@R.
Tugby, Matthew (2013) 'Causal nominalism as well as one over many problem.
231 Td (i )Tj 48 0 0 48 211 2995 Tm (11 )Tj 6.
(2013) 'Can topical insect repellents reduce malaria.
Tugby, Matthew (2013) 'Graph theoretic forms of dispositional structures.
mens nike free
mens nike free In certain English speaking environments,Red Bottom Outlet, people often consider '.
Has Jordans ever took a stance conceding everything that includes the inner city.
Inappropriate posts may very well be removed through the moderator.
grace Morganton, NC #16 Jan 16, 2012 sorparisjewellery.
small talk' being an important factor w Reply.
Sun bozo 3 Are teachers looking for far too much in taxes in th.
What happens young black men inside the inner cities do to possess a number of new Jordan shoes whenever they parents cannot stand them.
nike free australia
nike free 5.0 womens australia
nike free review
latest nike free run
nike shoes for women australia
nike free run 5.0 black and white


text:
For best performance, please check your browser settings for blocked content.
by family value from New York, NY
on February 1, 2010
Purchased a used car
Uses car for Transporting family
Does recommend this car
by average driver from Lubbock, TX
on March 29, 2011
Uses car for Just getting around
by caravany from Lexington, KY
on March 24, 2011
by Josephtrex from Erie, PA
on April 23, 2012
by Mike1624 from Rhode Island
on October 19, 2013
by vmaxdude2000 from rochester ny
on June 13, 2010
by Thank God and Dodge from Spokane, Wa.
on June 6, 2011
Does not recommend this car
by Dodge from Tampa, Florida
on June 7, 2010
Uses car for Having fun
by primeimages from Dublin, CA
on July 29, 2010
Uses car for Work
by Kpartida from Lindsay, Ca
on June 14, 2010


text:
Written on: 18/01/2011
I bought Acute Email IDs Production Engine from sagawebs.com last week and found it incredibly great!
This software is really simple to operate and I can now generate unlimited email lists using it. I am satisfied because its good in use and price. I was in the need of small help at a stage because I was doing some experiments with this software. I sent an email and got a reply within 15 minutes. This is the best thing you ever need while using any product.
So... in my opinion, this tool is best for every internet marketer who is in the need of email lists.
Recommended ! A++
As rated by our community of reviewers
" Only good for 3 years? " Read More
" Speedboost 9 and Driver updater simply the best! " Read More
" I love all the features of this software " Read More
" I remain bolt-stricken... " Read More
Written by AngelaDickens
" Incredible Program! Works great for small office! " Read More


text:
Written on: 03/01/2013 by plappen (114 reviews written)
V.E.A.R. Toward Success, Mike Caldwell, 2008, ISBN 9781425165260
This book shows how anyone can achieve their goals in any part of their life.
Vision comes first. For example, it's not enough to simply say to yourself, "I would like to open a cupcake shop." You have to visualize yourself in your shop which is full of customers, you have to dream about it, you practically have to make it part of your inner being. If you aren't totally committed to your goal, whatever it is, then why bother?
Next comes Energy. Visualizing, by itself, is not enough; what are you going to actually do about it? To continue the cupcake shop example, take a hard look at your finances, research the local health and safety requirements, and visit your local bank to start the loan process.
Your Attitude is an important part of reaching any goal. Are you a "glass is half full" or "glass is half empty" type of person? Well-meaning friends, and family members, may gently, or not so gently, question your goal. If you are totally committed to "it," whatever it is, are you going to let anyone steer you away from your goal? Can you look at a vacant, garbage-filled storefront, and visualize a clean, and busy, cupcake shop?
Last, but not least, is Resolve. There will be setbacks. There will be days when it seems like the whole world is conspiring against you, when curling into the fetal position and giving up is very tempting. This is when you find out what you are made of on the inside. Do you have what it takes to keep your focus on your goal, no matter how impossible it may seem?
This book can work with any type of goal, whether it's losing weight, or running an Ironman triathlon. The author may not have intended it, but this book also works as a cautionary tale for anyone who wants to build their own "off the grid" home in the woods (the author gives many examples from his own experiences). The goal may be "green" and noble, but, a seemingly infinite amount of patience and resolve may be needed to get there. On any level, this book is easy to read and follow, and is recommended for everyone.
As rated by our community of reviewers
Nothing new with this one unfortunately.
I always like Paul Mckenn... " Read More
" It is very insightful and helped me understand better my son's deve... " Read More
Written by Lulevy
" Contented Little Baby Book of Weaning is worth a read and can reall... " Read More
" Kaz Cooke's, The Rough Guide to Pregnancy and Birth is the best pre... " Read More
" Good, common sense approach to weaning - offering a great alternati... " Read More
Written by Jacobsmum


text:
Beauty Without Cruelty, Moisturizing Lipstick, Butterscotch 6, 0.11 oz (3 g) (Discontinued Item)
Out of Stock - Discontinued
Shipping Weight:?0.07 lbs (0.03 kg)Shipping WeightThe Shipping Weight includes the product, protective packaging material and the actual shipping box. In addition, the Shipping Weight may be adjusted for the Dimensional Weight (e.g. length, width & height) of a package. It is important to note that certain types of products (e.g. glass containers, liquids, fragile, refrigerated or ice packed) will often require protective packaging material. As such, these products will reflect a higher Shipping Weight compared to the unprotected product.
- Product Code: BWC-01505
- UPC Code: 5018744015056
- Package Quantity: 0.11 oz (3 g)
- Dimensions: 0.5 x 0.5 x 4.1 in, 0.06 lbs (0.03 kg)
Product Overview
- Long-Lasting Color
- Moisturizing Formula
- Smooth and Emollient
- Colors and Conditions Lips
- With Vitamin E and Apricot Kernel Extract
Contains no animal ingredients
Ricinus communis (castor bean oil), oleyl oleate, candelilla cera (plant wax), synthetic beeswax (blend of plant fatty acids/esters & alcohols), caprylic/capric triglyceride, ozokerite, glyceryl hydroxystearate, carnauba (plant wax), octyl methoxycinnamate, isodecyl neopentanoate, prunus armeniaca (apricotr kernel oil), tocopherol (vitamin E), benzophenone-3, propylene glycol, bha, propyl gallate, citric acid, [+/- (may contain) ci 15850, ci 15985, ci 16035,ci 17200, ci 19140, ci 42090, ci 45370, ci 45380, ci 45410, ci 47005, ci 73360, ci 77007, ci 77491, ci 77492, ci 77499, ci 77510, ci 77742, ci 77891, tin oxide, mica (crystallized minerals)].
Vegan and Vegetarian
Fragrance free.


text:
Is It Possible to Change The Timeout To Close 2nd Explorer
View Single Post
27 Jun 2011
Ultimate 32 bit
9 posts
(Better) Is It Possible to Change The Time To Close 2nd Explorer.exe?
I am experiencing issues with explorer.exe (I found many reports on the web on this), not showing drives or control panel icons, or stop responding (win 7 32 bit Ult.)
I set to open a separate process to explore windows and I got the chance to look for a better file manager and got Directory Opus and set it as the default file manager.
(I use a Dell Precision notebook with certified hardware)
The explorer is still used for some windows, mainly control panel and device and printers.
If the process stands there for a while, at some time, it will start to create issues. With a new 2nd explorer.exe is quite sure it will work.
Checking the task manager I see that the 2nd explorer.exe waits for about 45 s to exit after the last windows close. Is there a place where I could reduce this?
(waiting for some windows fix) The overall impact is quite reduced as I do not use explorer to browse files, but I would know if there is a place where I could set a shorter delay to close explorer.exe after the latest window closes.
Fabio D'Alfonso
Fabio D'Alfonso Web Site | Enabling Business Through IT
My System Specs
Ultimate 32 bit
View Public Profile
Find More Posts by dalfonso01


text:
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Q1 2014 Earnings Call
May 07, 2014 9:00 am ET
Erika Luib - Investor Relations Manager
John L. Higgins - Chief Executive Officer, President and Executive Director
Matthew W. Foehr - Chief Operating Officer and Executive Vice President
Nishan DeSilva - Chief Financial Officer and Vice President of Finance & Strategy
Graig C. Suvannavejh - MLV & Co LLC, Research Division
Joseph Pantginis - Roth Capital Partners, LLC, Research Division
Matthew G. Hewitt - Craig-Hallum Capital Group LLC, Research Division
Christopher S. James - Brinson Patrick Securities Corporation, Research Division
Keith Albert Markey - Griffin Securities, Inc., Research Division
Greetings, and welcome to the Ligand's First Quarter 2014 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Erika, Investor Relations for Ligand. Thank you, Erika. You may begin.
Erika Luib
Thank you, Devin. Welcome to Ligand's First Quarter Financial Results for 2014 and Business Update Conference Call. Speaking today for Ligand are John Higgins, President and CEO; Matt Foehr, Executive Vice President and COO; and Nishan DeSilva, Vice President of Finance and Strategy and CFO.
As a reminder, today's call will contain forward-looking statements within the meaning of federal securities laws. These may include, but are not limited to, statements regarding intents, belief or current expectations of the company, its internal and partner programs, including PROMACTA, Kyprolis and Duavee and its management. These statements involve risks and uncertainties and actual events or results may differ materially from the projections described in today's press release and this conference call.
Additional information concerning risk factors and other matters concerning Ligand can be found on Ligand's public periodic filings with the SEC, which are available at sec.gov.
The information in this conference call related to projections or other forward-looking statements represents the company's best judgment based on information available and reviewed by the company as of today, May 7, 2014, and do not necessarily represent the views of GSK, Pfizer, Onyx, Amgen or any of our other partners.
Ligand undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.
At this time, I'll turn the call over to John Higgins. John?
John L. Higgins
Thanks for joining us for our Q1 earnings call. Matt Nishan and I are in Boston today, participating in the Deutsche Bank conference, and we invite you to join us for the webcast presentation later today as well. We're on at 4:10 this afternoon.
The first quarter of 2014 was very strong financially and operationally. Financially, we enjoyed impressive growth in revenues over the same period last year, driven by increases in royalties and Captisol sales. We also saw a meaningful increase in cash and investments over the past year while paying down debt and more than doubling shareholders' equity.
Beyond the financial performance, the late-stage clinical and regulatory achievements by our partners this past quarter were especially impressive and clearly defined for investors the strength of our portfolio and business.
During the past few months, we saw numerous positive events, notably 2 new products launched from Merck and Pfizer, increasing our commercial partner programs from 5 to 7 revenue-generating assets. GSK filed yet another SNDA for PROMACTA, Lundbeck filed an NDA for Carbella, and Spectrum announced pivotal data for its Melphalan program, and anticipates an NDA filing later this year.
Beyond that, we saw many of our other partners announce data start trial and raise money in private and IPO financings. Overall, the biotech and pharmaceutical industries continue to enjoy a favorable regulatory environment and strong operating performance. Through our rich portfolio of partnered assets, we are participating in this positive business environment in many ways.
In addition to our partners' achievements, Ligand's R&D activities had been very productive. Now we'll talk through some of our recent works and investments, but our team is now generating clinical data on a lead diabetes program, its advancing novel research for a couple of promising new drug targets, strengthening the Captisol platform and its renewed clinical interest in SARM for investigator government and potentially partnered sponsored trials.
This productivity reflects Ligand's heritage in and research and sets us up to explore dealmaking with prospective partners and new licensees, as well as with IPO-tracked companies, seeking ways to principate with Ligand in its rich and highly successful R&D heritage.
With our business model, our goal is to answer key early scientific questions and its partner programs in creative ways to advance them through the clinic to the market. We are at a time, given the business environment, where there's more interest in Ligand's research and technology than any time over the past several years.
Before I turn the call over to Matt, let me provide comments on a few of our key programs.
First, in regards to PROMACTA, the program is doing very well fundamentally. New territories are being added for the HepC indication and another SNDA was filed for the drug, this time for aplastic anemia. This indication was designated as a breakthrough therapy and is eligible for 6-month review. We expect the FDA action date to be some time during the next quarter. Also, many late-stage trials are ongoing for oncology-related indications.
Now this past quarter, we saw sales for PROMACTA dip several percent lower than the prior quarter to $80 million. That's a bit lower than expected. We believe weather may have impacted U.S. sales, and foreign currency had some impact on emerging markets. We don't view the Q1 sales report as a reflection of the drugs' long-term prospects. We see PROMACTA as a young product with long patent life with new indications in markets for the product to expand into over the next few years.
Of note, Novartis announced it will be acquiring GSK's oncology unit, including PROMACTA. We believe Novartis could be a strong commercial team to support PROMACTA, and the company indicated in a recent presentation that they project NDA filings for PROMACTA in NBS and AML next year. For some market watchers, that is as much as 6 to 12 months sooner than might have been anticipated. We expect the Novartis' PROMACTA acquisition to close in the first half of 2015.
As for Kyprolis, the big event for Amgen's drug for multiple myeloma is due later this summer, with pivotal data expected from the ASPIRE and FOCUS trials.
Sales were flat this past quarter, consistent with other oncology drugs, which may be a reflection again of weather in the U.S. The Kyprolis pivotal data will be a major factor in the near-term, helping Amgen to determine if and when the product will be eligible for registration in Europe, as well as the eventual expansion in first line use. We are eager to learn the results from those studies.
In other news, Pfizer launched Duavee during the first quarter. This is a drug stemming from a license with Wyeth and Pfizer in the mid-1990s that, after a long development path, finally won approval in the U.S. late last year. The European filing is pending approval and we expect to know that outcome next quarter. Of note, on Pfizer's earnings call Monday morning, Pfizer CEO called out Duavee as 1 of 5 products to expect incremental revenue from in 2014. Also on the same call, the group president of global innovation advisor said one of their objectives is, and I quote, "leveraging our strong presence in the women's health category to launch Duavee in the United States as a potential new standard of care." It is great to see the public mentions by Pfizer's executive for this promising new therapy.
And finally, in other news, Merck received approval ahead of schedule for NOXAFIL IV, a capsule-enabled antifungal, and the product is now on the market. We received a $1 million milestone payment in March, and that is ahead of schedule as we had originally expected the FDA approval and milestone to occur in the second quarter.
And now, I'll turn it over to Matt.
Matthew W. Foehr
Thanks, John. I'm going to make some additional comments about our partnered and internal unpartnered pipeline assets, as well as the platform technologies that we are investing in to fuel future shots-on-goal. John touched on the commercial, clinical and regulatory progress by some of our Captisol partners who are in late-stage development or who are now commercial. These programs illustrate that the role of Captisol can play in creating novel differentiated products with existing active ingredients and creating what one could consider higher-probability shots-on-goal as you compare it to published industry average success rates for products in development. I want to point out that beyond the validation from these established Captisol programs, the inbound interest in Captisol has increased significantly in our time with the technology. We continue to see more potential partners requesting samples of Captisol and the commercial and regulatory success of Captisol-enabled programs continues to create positive visibility for the technology.
Recently, a few of our early-stage Captisol partners in private or recently public companies have really been on the move, moving ahead our partnered programs and successfully building out their teams and structures. Our partners at Sage Therapeutics have been reporting significant progress on SAGE-547. It's now in the clinic for super-refractory status epilepticus, and they also reported the receipt of orphan designation last week. Sage has also succeeded in a couple of large financings with some Blue Chip investors and are quickly moving the program ahead. Also Curex, which is a private company based near Ligand and San Diego, is moving ahead with plans for a Phase II for Captisol-enabled Topiramate, which we licensed to them last year.
Another company have also had recent progress in developments, and that's Aldeyra Therapeutics. Friday of last week, they completed their IPO to raise funds to support the development of an asset on which we are a partner. Aldeyra's lead program is Captisol-enabled NS2.
MEI Pharma continues to advance its pipeline of exciting oncology drugs with unique mechanisms. On Monday, they announced the first patient had been dosed in a Phase Ib study of its mitochondrial inhibitor drug candidate ME-344, which is also Captisol-enabled. They're testing it in combination with Hycamtin in patients with solid tumors, including small cell lung and ovarian cancer. Preliminary data from this study is anticipated to be available in the first quarter of next year. And last year, MEI presented results from a Phase I study of ME-344 and showed evidence of single-agent activity in patients with refractory solid tumors, showing 38% of patients who achieved stable disease or better.
As a business, our goal is to provide excellent customer service to our Captisol licensees. It's the right way to do business and it makes the technology licenses even more valuable to our partners and it's a way to confirm more value with the licenses. I'm quite proud of the service that our team provides to our partners, and we routinely receive positive feedback, praising our team's responsiveness, ability to manage and answer technical questions and thanking us for the valuable help that we provide as they move their programs through development.
In addition to that, they also realize that when paired with their active ingredient, whether that is an existing active that is coming off patent or a novel active that has never been tested in humans before, that Captisol has the ability to truly make a product.
Recently, a scientist at one of our pharma partners, when completing one of routine customer surveys, noted to us that, "I have found Captisol be nothing short of a miracle when trying to formulate compounds that are difficult to dissolve."
Outside of Captisol licensees, another partner that I want to comment briefly on is Viking Therapeutics and the progress that they are making we their FPPA diabetes program, VK 0612. We signed a deal with Viking in 2012 for FPPAs, which is a potential novel mechanism for treatment of diabetes, which is obviously a huge global market. Viking now has a highly experienced team in place, driving towards a clinical Phase IIb initiation later this year, and Ligand has a potential for meaningful downstream economics, including over $38 million in clinical and regulatory milestones and tiered royalties on potential commercial sales.
Switching gears now to our internal programs. We plan to present our Phase I data for our glucagon receptor antagonist next month at the ADA meeting in San Francisco. We feel we have a more potent molecule with improved properties from what's in development by other companies. And there are a limited number of molecules with novel mechanisms in development for diabetes, and this program has a chance to be a major novel player in the diabetes space.
Also, with increased high-profile interest in the metabolic space, specifically related to NASH and obesity, we are seeing an increase in the partner interest related to some of our metabolic assets, specifically our TR Beta program and our DGAP program.
We are also progressing our IRAK4 program. IRAK4 is an interesting discovery program where we feel have a leading scientific position. IRAK4 plays an important role in the innate immune system and may also be important for crosstalk between the innate and adaptive immune systems. IRAK4 is a signaling component downstream of both toll-like receptors and Interlukin-1 receptors, suggesting that it may have therapeutic value for a range of autoimmune and inflammatory conditions. Inhibition of IRAK4 activity has been implicated in multiple diseases, including rheumatoid arthritis, lupus, gout, inflammatory bowel disease, asthma and allergic rhinitis. Inhibitors from IRAK4 may also be useful for the treatment of certain leukemias and lymphomas. We have identified orally available small molecule inhibitors of IRAK4 and are working in models of cancer in autoimmune disease to position them for partnering. We're currently targeting presenting new data for this program at a scientific meeting later this year.
So our R&D engine is functioning very well at Ligand. We focus our efforts on answering questions to drive partnering of assets and also on creating and supporting novel platforms that meet needs in the industry and that can be the subject of future partnering.
Our goal is to make focus R&D investments to be responsive to the scientific and deal landscape and translate our investment into fully funded partnerships downstream.
And with that, I'll turn the call over to Nishan to review the Q1 financials.
Nishan DeSilva
Thanks, Matt. I'll recap just a few of the highlights from our earnings release issued earlier today. Total revenue for the quarter was $16 million, up $4.4 million compared to the same quarter last year, driven primarily by an increase in Captisol material sales by $4.2 million and an increase in royalty revenues by $2.1 million, which largely reflected higher PROMACTA royalties. These increases were partially offset by $1.9 million lower license and milestone revenue. Last year's quarter had a $3 million upfront payment for the Captisol-enabled Melphalan licensing deal that we executed with Spectrum Pharmaceuticals, leads the higher license and milestone revenue in the year-ago period.
Our cost of good sold for the quarter was $2.5 million, resulting in gross margin on material sales of 56%, similar to the year-ago period. In addition, our cash, G&A and R&D expenses were virtually flat compared to the same quarter last year.
For the quarter, we reported non-GAAP income from continuing operations of $7.3 million, or $0.35 per diluted share, compared to $4.4 million or $0.22 per diluted share for the same period last year.
On the cash side, we ended the quarter with $26.6 million of cash, short-term investments and restricted cash, which is ahead of our plan and higher than last year while continuing to pay down debt. We have a small debt balance of $5.8 million remaining that is scheduled to be paid off over the next 3 months.
Now as we look forward, one change for revenue outlook that we just became aware of relates to AVINZA. Pfizer recently notified us that a generic product entered the market for AVINZA in February. While we are entitled to continue to earn royalties until 2017, with the generic on the market, we expect our royalties will decrease.
As background, AVINZA is late in its commercial life and is a relatively small product for Ligan. Sales have been declining for years and we are in a 5% royalty. During 2013, the quarterly AVINZA royalties was, on average, about $825,000. For the second quarter of 2014, we expect the AVINZA royalty to be about $350,000. And after that, we anticipate our quarterly royalties for AVINZA to be in the $50,000 to $100,000 range.
For 2014 outlook, we reaffirm our previous guidance of total revenues between $62 million and $64 million and non-GAAP earnings per diluted share between $1.40 and $1.45. While AVINZA royalties will be lower going forward, at this time, we believe other factors within Ligand's business will help offset that variance and keep our revenues and earnings in our original range.
For the second quarter, we expect total revenues to be between $9 million and $9.5 million and non-GAAP earnings to be between $0.11 and $0.13 per diluted share.
As expected, the revenue outlook for Q2 is lower than our reported Q1 revenue. As we have said on past calls, our quarterly revenue is lumpy due to royalty rates that reset annually to lower tiers that we see at the start of our calendar year and due to the timing of milestone payments in large Captisol rollovers that we saw in Q1. Our non-GAAP earnings per share guidance for both the full year and the second quarter exclude changes in contingent liabilities, mark-to-market adjustments for amounts owed to licensors and stock-based compensation expense.
With that, I'll turn the call over to the operator and open it up for questions.
Question-and-Answer Session
[Operator Instructions] Our first question comes from the line of Graig Suvannavejh with MLV & Co.
Graig C. Suvannavejh - MLV & Co LLC, Research Division
You know I think all of us are impressed by the results you just posted. But clearly, where you are on the second quarter in terms of guidance is below where we were. And while we understand that AVINZA is part of that, can you just give us a sense maybe of how comfortable you are right now with your thoughts around the Captisol business? And where -- I guess, where might there be sources of upside relative to your guidance for the second quarter?
John L. Higgins
Graig, thanks for the question and participating on the call. We're now 5 weeks into the quarter, so we've got some visibility on the Captisol orders and so on. As you know, we book on a one-quarter lag for royalties so we know essentially what the royalty numbers are. So in terms of upside, there is a potential for licensing that may be done ahead of schedule. As we saw with the Merck milestone, there could be some small milestone event that might happen ahead of schedule. The Captisol orders, we do the best jobs to predict. We get long-term forecast for commercial orders. The clinical orders are not as predictable. But generally, although there's a lot of variables in our business, and we're very pleased with the financial performance and outlook, this outlook for Q2 seems reasonable and in line. As Nishan just mentioned at the end of his call, it's completely in line with our expectation except for the Merck milestone. That $1 million, instead of Q2, it was a pull forward to Q1. So aside from those timing events, the outlook for the full year is unchanged.
Graig C. Suvannavejh - MLV & Co LLC, Research Division
Okay. Maybe there's 2 more questions before I jump back in the queue. In terms of your R&D, it sounds like you're very productive in terms of the early stage compound. How are you prioritizing where you spend your R&D? And maybe give us a sense of -- given your current R&D budget, where kind of the percentages are on certain projects and/or platforms? You highlighted some interesting platforms as well.
Matthew W. Foehr
Yes, Graig, thanks for the question. This is Matt. We have probably 20 programs we could invest in and we look at a number of factors when we select programs to invest in. One is we look where we can answer key questions that are going to significantly increase the partnerability of an asset, also where maybe external science is starting to ripen and also where licensing landscape or were there's a demand for certain assets. So we take all those and some other things into account as we look at them. I'll say, a couple of years ago, we made the decision to start investing in the glucagon receptor antagonist program, knowing that there was a significant need for novel therapies in diabetes. We've continued that investment. We feel very good about that investment. And now we're at a point where we'll be presenting new human data next month at the ADA. Also, program like IRAK4, where we've got a commanding position, an early position from an IP and discovery perspective, that's another type of program where we see a high -- an opportunity to answer key questions to then drive partnerability. So it's a mixture effect.
John L. Higgins
And I'll just add, we're at a unique place with our business model where we can be very objective on what we choose to fund. This is significant. A lot of biotech companies, they're therapeutically focused or they have a real infrastructure in, let's say, in the commercial or manufacturing area. And those factors often drive the prioritization of programming. At Ligand, we look carefully at the competitive environment, the market potential. We look at the IP of our respective programs, and as Matt alluded to, the general market demand. So we're focusing on answering those are the questions, but we're funding what we think are the priority programs, and periodically, we're able to pull other programs into our R&D investments.
Graig C. Suvannavejh - MLV & Co LLC, Research Division
And then my last question, just with respect to Duavee, we're all pleased to hear Pfizer's comments around its support of that product launch. My question is at what point do you think, given product launches tend to be slow, at least most of them are, we've seen some examples of one being very fast, but at what sense do you -- at what point do you think we'll get a better sense of how that revenue trajectory of this particular product might look like?
John L. Higgins
Yes, great question. Pfizer, as you can imagine, a very big company, well-established women's health commercial organization. We are spending more time trying to build that relationship and get information about their commercial planning and outlook. We don't have much information right now, frankly. Our expectation, though, is that once Europe comes online, approval targeted for next quarter, over the next 6 to 12 months is where your going to see global planning and really more, I think, tangible evidence of what the trend lines are. It's early days. But the category, it's a multi-billion dollar existing category. It's our opinion that this is the best-in-class molecule, and Pfizer genuinely seems committed to it. So we're at a bit of a changing environment for the women's health category. It's not going to be a flip-the-switch commercial response, but I think the environment is very positive. And our view is that it's going to take 6 to 12 months before we really start to see the evidence of trend.
Matthew W. Foehr
Yes, and Graig, just a couple of factors, obviously, on the segment itself. Obviously, the number of women in the U.S. with post-menopausal symptoms is expected to be over 50 million by 2020. It's a big category, as John was saying. 70% of those women are not being treated at all for their post-menopausal symptoms and a large portion of those, about 60-plus percent, haven't even pursued treatment for the symptoms. So there's a big potential there.
John L. Higgins
Yes. And it's calling on the doctors, getting them familiar with the medicine, but also, frankly, changing the patient's knowledge and expectation for potential new therapies. So that takes some time. But we're -- again, we're pleased to see the public commentary out of Pfizer's executives around the brand.
Our next version comes from the line of Joe Pantginis with Roth Capital Partners.
Joseph Pantginis - Roth Capital Partners, LLC, Research Division
Let me start on PROMACTA, a couple of little points there. I was just wondering if you have any color regarding how the market is splitting up in HepC with regard to U.S. and the, as you mentioned, additional territories, and also Europe.
Matthew W. Foehr
Yes, thanks, Joe. Obviously, the HepC landscape is a dynamic one. And everybody knows PROMACTA has always been designed to treat that sickest subset of patients whose livers are failing or have failed, and to get them to a point where their platelets can be boosted. GSK has reported contribution, growing contribution from HepC in the U.S. and Europe. Now they've expanded into close to 50 markets for HepC, so that global expansion and rollout is still occurring. We expect that they'll continue expanding until they reach the 94, 95 markets that PROMACTA is in for ITP. So still in its expansion phase, still rolling out, but still a significant contributor.
John L. Higgins
Yes. And there's no specific quantification by GSK in terms of ITP or HepC. Qualitatively, the recent development in the HepC space is perhaps not helping the analytics. At one hand, it is absolutely bringing more patients into the doctors office and creating more awareness. On the other hand, as you can imagine, there's been a real preoccupation with the new therapy. So on balance, this is an important medicine for a subset of the sickest patients, but one that is one of a kind. I mean, it is unique in what it does, in how it supports those patients, and to our knowledge, there's no other competition out there. So the HepC story is in its very early days, still.
Joseph Pantginis - Roth Capital Partners, LLC, Research Division
So actually, I don't want to overstate because you just mentioned, obviously, some of the issues regarding the direct antivirals in the U.S. and what have you. So would you anticipate some encouraging support for the PROMACTA franchise x-U.S. because interferon will still sort of remain a mainstay of therapy because they are non-genotype 1 viruses primarily?
Matthew W. Foehr
Yes, absolutely, Joe. And I think that's part of the rationale for the aggressive global expansion for the indication is that the expectation is that those interferon therapies will be around for a long time in those markets.
John L. Higgins
And somewhat related, we made comments in my remarks about the Novartis acquisition. Novartis is acquiring GSK's oncology division. PROMACTA is a part of that. We have been very pleased with GSK's management of the asset and frankly, everything they've done with it. It's still 9 months out before that deal closes, but we think that this drug in Novartis' hands commercially, we view as a positive. We're pleased with what GSK is doing, whatever GSK's rationale was for divesting their business unit is there call. But the Novartis commercial infrastructure, we view as going to be a net incremental positive for all of the indications, the ITP, the hepatitis and potentially, the future oncology indications.
Joseph Pantginis - Roth Capital Partners, LLC, Research Division
No, sure. And then just to wrap up on PROMACTA. You did mention, I believe, that you're looking for a supplemental NDA filing in 2015 for NDF MAL and I was just curious, is that more of a supportive care study at this point?
Matthew W. Foehr
Yes, at this point. They've got a number of studies ongoing, but -- and they haven't disclose that -- the exact -- how the indication will be defined in NDF MAL, just that they plan a filing in 2015.
Joseph Pantginis - Roth Capital Partners, LLC, Research Division
Okay. And do you expect that will see additional data that will support sort of the anecdotes today with regard to the disease-modifying potential of the drug?
Matthew W. Foehr
I would, Joe. I -- GSK has been very prolific in publishing at all of the relevant global and regional hematology meetings, and we expect that to continue. They're generating a lot of data. Obviously, over 25 active clinical trials, far more that when you include the investigator work. So there -- we would expect to see a continued flow on that data.
Joseph Pantginis - Roth Capital Partners, LLC, Research Division
Great. And my last quick question, if you don't mind. Just regard to 6972, can you characterize sort of the discussions you've had to date, or the level of maturity of these discussions? Could one assume that you have potential partners for 6972 sort of waiting in the wings for these data to be presented at ADA?
Matthew W. Foehr
Yes, Joe. I'll say we're just at the point now. The data is coming in. We're preparing it and reviewing it. We're excited about our presentation in mid-June at ADA. We, of course, get inbound calls from the folks you'd expect, but no real kind of detailed update on maturity of those discussions, Joe.
John L. Higgins
And generally, though, diabetes, huge category. We have, we believe, strong IP. We're pleased with the data we have so far. Lilly continues to conduct late-stage studies. Some other companies are indicating that they're working in the field. So we do believe this is a very solid area to be participating in on the research side.
Our next question comes from the line of Matt Hewitt with Craig-Hallum Capital Group.
Matthew G. Hewitt - Craig-Hallum Capital Group LLC, Research Division
A couple of questions for me. First, regarding Merck and the NOXAFIL opportunity. How is that progressing since they've received FDA approval? How should we be thinking about the ramp, I guess, as this year progresses and going forward into '15?
Matthew W. Foehr
Yes, thanks, Matt. This is Matt Foehr. They, very quickly -- as we said, they got approval earlier than expected. We're very pleased to see that shortly thereafter they made the product available. It was a very quick launch. It's still probably too early to comment on it, but it's clear that it's a high-priority program for them. We've been very impressed with the resource they're putting behind it and the team they've got on it. Obviously, they have a global footprint for the oral form for NOXAFIL already and so we feel very good about this drug in their hands.
Matthew G. Hewitt - Craig-Hallum Capital Group LLC, Research Division
Okay, great. And then as far as SARM is concerned, are there -- how have the partnering opportunities evolved so far this year?
Matthew W. Foehr
So the interesting developments around SARM, and just a little history for those who may not be as familiar as with it, it's a selective androgen receptor modulator. It's an area of research that Ligand really was the pioneer in about 15 to 18 years ago. We conducted some early studies a couple of years ago. Got encouraging data not only safety, but also in healthy volunteers, some real activity of drug efficacy. The interest is coming from the perspective of partners, some international companies, as well as investigators, and even, there's been some inquiries from government sources that wants to advance research in this area. So we are pleased of, one, with our are package. The market is evolving. There's another company that has a SARM that completed some Phase III studies and they're advancing their discussions with the regulatory agencies in Europe and in U.S. We believe that we're drafting in some of their progress. They may still have some clinical work left, but also the area muscle weight thing, muscle help, is a big field, and we're just in the process of working with various partners to navigate our path forward for getting that drug back into the clinic.
Matthew G. Hewitt - Craig-Hallum Capital Group LLC, Research Division
Okay, great. And maybe one last one for me. As far as PROMACTA is concerned, any update on the potential for a pediatric indication?
Matthew W. Foehr
Yes, Matt. So we expect -- GSK completed a Phase III in pediatric ITP in the last few months. We expect that data will be presented fairly soon. So that was a large Phase III study. It's important to note half or over half of the new diagnoses of ITP annually are in pediatric patients. So a big opportunity for growth for PROMACTA. So we expect to see that data in the coming months.
Our next question comes from the line of Christopher James with Brinson Patrick Securities.
Christopher S. James - Brinson Patrick Securities Corporation, Research Division
My first question is regarding the upcoming data at ADA with your glucagon receptor antagonist. How should we think about -- as you sort of saw through the data, how should we think about procuring in advance to interpret some of these data relative to other glucagon antagonists? I'm assuming we're going to see data on fasting blood glucose and PK-PD. But how should we think about sort of these data with respect to other compounds in development?
Matthew W. Foehr
Yes, Chris, thanks. We specifically designed this first-in-man study to answer as many questions as possible, and included both healthy volunteers, as well as Type 2 diabetics in the trial. So obviously, we'll get a full suite of PK-PD data, also some indications of efficacy as well. So we really felt very good about the design. And I was very pleased the team did a great job working with the FDA to design and define a trial that will answer a lot of questions and provide some insights into our molecule. We feel we have a more potent molecule than what's currently in development. And have what could be a best-in-class in this mechanism of action. So that's kind of the general summary, obviously. We'll present the data in the middle of June, and we're looking forward to getting it out there.
Christopher S. James - Brinson Patrick Securities Corporation, Research Division
Okay, great. Speaking of the FDA, is there a plan to meet with FDA after completion of the study, or will you wait for partnership?
Matthew W. Foehr
Yes. So we've had -- like in any IND, obviously, we had ongoing interaction with the FDA, leading up to our IND and afterwards. We feel like we understand the plan based on those discussions. There'd be really no need to have too much further dialogue. Obviously, we submit protocols for future studies, et cetera, as one normally does with an IND.
Christopher S. James - Brinson Patrick Securities Corporation, Research Division
Great. And I think we were -- just moving on to the base inhibitor. We were, I think, expecting an update from Merck. I personally did not see a whole lot that from the Analyst Day regarding that program. Have you had a chance to meet with them or discuss this program with Merck?
Matthew W. Foehr
Yes, I'm pretty sure -- you're probably referring to the Merck's R&D day, which was yesterday. I think they -- in their plan that they have mapped out in advance, were covering other programs. They did discuss the base inhibitor briefly and reiterated their commitment around the program. Obviously, they got 2 large Phase III trials running now. Those won't read out for a little while. But we continue to see them as being very committed and excited about those programs.
Christopher S. James - Brinson Patrick Securities Corporation, Research Division
Great, thanks. And then a quick PROMACTA question before I wrap up. I think we have -- so now we have a good sense of timing around approval in aplastic anemia. Do you have a better sense of the size of the opportunities there? I think you mentioned last time, there are about 10,000 U.S. patients. Do you have a sense of sort of what the size and scope of this could be?
Matthew W. Foehr
Yes. That's about right, Chris. It's obviously a niche indication. It's one that these patients really have very limited-to-no-treatment options, the data that was presented at E-Hall last year was really very exciting, not only for the patient population, of course, but also scientifically, suggesting, as was said in the title of the presentation, potential curative effects of PROMACTA in aplastic anemia. I think that's why it has moved so quickly through the regulatory process so far. So -- but yes, you're generally in the right range, I think, in terms of the opportunity. We're excited to see that progress and hopefully get rolled out.
Our next question comes from the line of Keith Markey with Griffin Securities.
Keith Albert Markey - Griffin Securities, Inc., Research Division
Just a quick question for you about the Captisol-enabled drug program. How many clinical trials are currently ongoing with those drugs and how would you expect that number to change in 2015?
Matthew W. Foehr
Yes. Keith, it's growing all the time. The only reason I -- it's hard to give you an exact number is we've -- we get more and more requests for IND cross-reference letters. We got more partners starting more and more trials and more indications. It's grown significantly over the last years.
John L. Higgins
Yes. There's probably, right now, this year, 24 to maybe over 50 trials ongoing for Captisol.
Matthew W. Foehr
Yes, yes. I think that's about right, and it's growing.
John L. Higgins
It could be double from where it was 3 or 4 years ago.
Matthew W. Foehr
Keith Albert Markey - Griffin Securities, Inc., Research Division
Okay. And what does that equate to in terms of the number of drugs, do you think?
John L. Higgins
Well, the way we look at this, as you know, we quote our portfolio of shots-on-goal, our fully funded partnerships or programs, and we have over 90. And a rough estimate, probably 2/3 are Captisol-related. And so some of those are the same program for 2 or 3 indications, but they're probably over 50 distinct programs and/or molecules and over 60 different indications. So a very significant element of our portfolio. And one that, Matt -- he referenced the customer service, but we're getting real-time feedback not only on the utilization, but the quality of the service and what the technology does to make drugs possible.
Keith Albert Markey - Griffin Securities, Inc., Research Division
Okay, well, thank you. But a part of my question had to deal with perhaps the outlook for Captisol-enabled -- well, Captisol sales for 2015? Do you see that going up since some of the clinical trials might be coming to fruition in the near future? Or do you see it as going up because more drugs will be in clinical trials?
John L. Higgins
Well, so generally -- I mean, we gave our outlook for 2015 revenue several months ago. Our outlook hasn't change. It was north of $80 million. The 2 factors that are driving Captisol demand is, one, to your point, the number of clinical trials. We've got more partners, drugs in development, and as those programs are successful, they're moving into larger studies. Frankly, early studies, pre-clinical, Phase I, they're using Captisol, but their requirements may be small. As they move into Phase II or III trials, that's where we're seeing orders in customers. Also as products go commercial. We know Kyprolis. We now have NOXAFIL. We may have Carbella Lundbeck's drug approved at year end. That's another factor, but the outlook, yes, we get -- outlook from customers on a 3- to 12-month basis, obviously, we account for that in our current-year guidance, but we're not getting any more granular on 2015. But generally, the trends, the demand for Captisol, the interest, I'll say the success of that technology is clear and growing.
There are no further questions at this time. I'd like to turn the floor over to Mr. Higgins for closing comments.
John L. Higgins
Thank you. Well, appreciate everybody's interest and time on the call this morning. We're pleased with the start of 2014, not only financially. We are heartened, particularly by the improvement in our balance sheet, stronger cash position, significant increase in shareholders' equity. Debt is going down. It's real evidence that this business model is successful. We've always said, "you haven't created real value until you have created or generated sustainable cash flows." And now a few quarters into generating profits and cash flows, there's more clarity and evidence of the momentum of our business model than ever before. Also, while we highlighted several of our programs today, the late-stage royalty assets, as well as some of the earlier programs, our portfolio has never been larger. And frankly, we've never had a calendar with more significant news events coming up in the next 6 to 12 months. So on balance, we are very pleased with the business.
Today, we are at the Deutsche Bank conference. We'll be presenting at 4:10. We'll have some slides in our corporate investor deck. And later this month, we'll be participating in the Bank of America conference. And at the end of May, at the Craig-Hallum Investor Conference. So we look forward to being in the road and meeting with investors and giving you more updates to our story. Thanks for joining us.
This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!


text:
Here are the picks for today's start of horse racing at the Alameda County Fair.
2. High and Special...Hit board here last year. Kishmia...Good move over track to prep. Remarkable Cartel...Past class better than the rest.
3. Rambunchkie...Might get loose on the front end. Chat With Dixie...Has run well vs. better. Mt Aunt Annie...Beaten twice by the No. 1.
4. Dream of Daisy...Will have pace to run at Halo La...Shows speed, Baze takes the call. Promiscuoussuances...Horse has seen better days, has speed.
5. Pulpit Hanna...Works, connections say ready. Urgraceisenough...Expect big improvement off debut. Rock Your Baby...Price play, been working over track.
6. Runninforbackpay...Closer, will have pace to run at. Wine and Song...Speed, caught and nosed in last. Unmatched Force...Has a lot of speed.
7. Perfect Meeting...Solid works over track coming off break. Giant Journey...Bullet work followed by maintenance drill. Sneezy Beezy...Should be a great spot.
8. Unbridled Falls...Big drop, looks ready for return. Red Terrace...Working over track, gets Baze. Spot N the Line...Decent effort, had trouble in debut.
This story contains 215 words.
If you are a paid subscriber, check to make sure you have logged in. Otherwise our system cannot recognize you as having full free access to our site.
If you are a paid print subscriber and haven't yet set up an online account, click here to get your online account activated.


text:
Calciomercato.com claim that the Ghanaian will be the next big name signing for the big spending Ligue 1 side.
Monaco have already signed Ricardo Carvalho, James Rodriguez and Joao Moutinho, and are also set to sign Radamel Falcao and Victor Valdes.
More about...
What is your opinion? Feel free to discuss the article under. You have to comment by using your Facebook profile. Be fair and have respect for other people and opinions!
Summer 2016 is set to be a very exciting time for football fans, as this is when the long awaited Euro 2016 tournament kicks off.
Since Guus Hiddink arrived at the helm, Chelsea have improved considerably after a tricky start to the campaign.